[Therapy-resistant hypertension--the value of aldosterone antagonists].

Uncontrolled studies suggest the benefits of an add-on antihypertensive therapy with an aldosterone receptor antagonist. However, it still must be clarified whether a PHA screening has a predictive value for the efficacy of a therapy with an aldosterone receptor antagonist. Before generally accepted recommendations can be made, a randomized, controlled study with aldosterone antagonists must prove that such a therapy is safer, tolerable and leads to better long-term blood pressure control as well as lower renal and cardiovascular morbidity and mortality.